Catalog No.
Product Name
Application
Product Information
Citations
-
Drug Impurity
Mivacurium chloride impurity 6 is a known impurity associated with the neuromuscular blocker Mivacurium chloride. It serves as a critical reference compound for quality assurance and method validation in pharmaceutical development. This impurity can be utilized in analytical studies to assess the purity of Mivacurium chloride formulations and to understand potential effects on safety and efficacy in drug manufacturing processes. -
Drug Impurity
Dexamethasone impurity 2 is a chemical impurity associated with Dexamethasone. It serves as an important reference standard for purity analysis and quality control in pharmaceutical research. This compound aids in the assessment and characterization of Dexamethasone formulations, facilitating compliance with regulatory standards. -
Degradation Impurity in Docetaxel
7-epi-10-Oxo-10-deacetyl baccatin III is a degradation impurity found in Docetaxel. This compound is important for research involving the stability and degradation pathways of taxane-based chemotherapeutics. It serves as a vital reference standard for evaluating the purity and efficacy of Docetaxel formulations, thus aiding in the development of stable therapeutic agents. -
Drug Impurity
Cyclosporin impurity 2, also known as Acetoxy cyclosporin A acetate, is a known impurity of cyclosporin. This compound may arise during the synthesis or formulation of cyclosporin and can be important for analytical and quality control purposes in pharmaceutical research. It serves as a reference standard for the evaluation of cyclosporin purity and plays a critical role in the assessment of drug safety and efficacy. -
Drug Impurity
(2,3-Dimethoxyphenyl)methanol is identified as a drug impurity often encountered during the synthesis of various pharmaceutical compounds. Its structural features may influence the physicochemical properties of the primary drug substance. This compound is relevant for analytical studies focused on purity assessment and stability testing within pharmaceutical research and development. -
Drug Impurity
Ranolazine impurity 10 is a chemical impurity associated with the cardiovascular drug Ranolazine, which primarily targets sodium channels. This impurity is significant for analytical and quality control purposes in pharmaceutical research and development, aiding in the assessment of the drug's purity and safety profile. Its identification and quantification are critical for compliance with regulatory standards in the drug manufacturing process. -
Drug Impurity
Fingolimod impurity 3 is identified as a chemical impurity associated with Fingolimod, a sphingosine 1-phosphate receptor modulator. This compound serves as an important reference for assessing the purity and quality of Fingolimod formulations in pharmaceutical research. Its presence may influence the pharmacological profile and efficacy of the parent drug, making it a valuable component in analytical studies and quality control processes. -
Drug Impurity
Rivaroxaban impurity 69 is a chemical impurity associated with the anticoagulant drug Rivaroxaban. It is commonly utilized in analytical research to assess the purity and quality of Rivaroxaban formulations. Understanding the presence of this impurity is critical for ensuring the safety and efficacy of therapeutic applications involving Rivaroxaban. -
Drug Impurity
Vortioxetine impurity 9 is a synthetic byproduct of the cognitive enhancer Vortioxetine, primarily serving as a drug impurity reference standard. This compound is relevant in analytical chemistry for the assessment of Vortioxetine purity and stability. It is essential for quality control in pharmaceutical research and development, ensuring compliance with regulatory standards during drug formulation and testing. -
Drug Impurity
Febuxostat impurity 11 is a chemical impurity associated with Febuxostat, an inhibitor of xanthine oxidase. This impurity is crucial for the quality control and characterization of Febuxostat in pharmaceutical formulations. It is primarily used in the development and validation of analytical methods to ensure the purity and safety of drug products containing Febuxostat. -
Drug Impurity
Cyclosporin impurity 1, also known as Isocyclosporin H, is a known impurity found in cyclosporin formulations. Its characterization is critical for ensuring the purity and efficacy of cyclosporin-based drugs. This compound may be utilized in quality control settings to monitor the presence of impurities in pharmaceutical products and help assess their impact on biological activity and safety. -
Ivermectin Impurity
Imidacloprid impurity 1 is an impurity associated with the synthesis of Ivermectin, a key antiparasitic agent. This compound may be utilized in research to assess the stability and purity of Ivermectin formulations, as well as in studies focused on the synthesis pathways of related compounds. Its role in the evaluation of pharmaceutical products makes it a valuable tool in chemical and pharmacological research. -
Drug Impurity
Prasugrel impurity 12 is a known impurity associated with the chemical synthesis of Prasugrel, an antiplatelet agent. This compound is crucial for understanding the purity profile of Prasugrel during drug development and quality control processes. It serves as a reference standard for analytical methods, aiding in the identification and quantification of impurities in pharmaceutical formulations. -
Drug Impurity
Rosuvastatin impurity 20 is a chemical impurity associated with the statin medication Rosuvastatin, which primarily targets HMG-CoA reductase. This impurity can be used in pharmaceutical research and development to assess the quality and purity of Rosuvastatin formulations. It assists in method validation and regulatory compliance during the drug manufacturing process. -
Xanthorrhizol Impurity
Xanthorrhizol impurity 1 is a chemical impurity associated with Xanthorrhizol, a natural compound known for its diverse biological activities. This impurity may influence the pharmacological properties of Xanthorrhizol and is significant for ensuring the quality and safety of research applications. Its characterization is essential for studies exploring the therapeutic potential and mechanisms of Xanthorrhizol in various biological systems. -
Drug Impurity
Rivaroxaban impurity 32 is a known impurity associated with the anticoagulant drug Rivaroxaban. This compound serves as an important reference standard for analytical and quality control purposes in pharmaceutical research. It aids in the assessment of drug purity and stability, facilitating the development and validation of analytical methods in drug formulation and safety studies. -
Drug Impurity
Azithromycin impurity 15 is a chemical impurity associated with Azithromycin. It may impact the efficacy and safety of formulations, making it essential for quality control in pharmaceutical development. This reagent is relevant for analytical research, stability studies, and method validation to ensure compliance with regulatory standards in drug manufacturing. -
Drug Impurity
Cyclosporin impurity 3 is identified as a structural impurity associated with Cyclosporin. It is utilized primarily in pharmaceutical research to ensure the purity of Cyclosporin formulations and assess the impact of impurities on drug efficacy and safety. This compound is essential for quality control procedures and analytical studies in drug development. -
Drug Impurity
Prasugrel impurity 6 hydrochloride is a notable impurity of Prasugrel hydrochloride, characterized by its structure as 4-Fluoro prasugrel hydrochloride. This compound is primarily relevant in the analysis and quality control of Prasugrel formulations. Its presence can be critical for ensuring the purity and efficacy of drug products in pharmaceutical research and development. -
Drug Impurity
Azilsartan impurity 8 is a synthetic impurity related to the drug Azilsartan, an angiotensin II receptor blocker. This compound is primarily utilized in pharmacokinetic studies and quality control processes to assess the purity of Azilsartan formulations. It serves as a critical reference standard for ensuring compliance with regulatory specifications in pharmaceutical development and manufacturing. -
Drug Impurity
Mirabegron impurity 10 is a known impurity associated with the pharmacological agent Mirabegron, a selective beta-3 adrenergic receptor agonist. It is crucial for studies focused on drug purity and stability, as well as for understanding the synthesis and degradation pathways of Mirabegron. This impurity serves as a reference standard for analytical methods and quality control processes in pharmaceutical development and research applications. -
Drug Impurity
Duloxetine impurity 10 is a characterized impurity of the antidepressant Duloxetine, primarily targeting serotonin and norepinephrine reuptake inhibition. This reagent serves as a critical tool for analytical chemistry applications, including the assessment of drug purity and the development of quality control methods. Its presence in formulations can have significant implications for pharmacokinetics and pharmacodynamics, making it essential for comprehensive drug analysis and regulatory compliance. -
Drug Impurity
Trazodone impurity 2 hydrochloride is a chemical impurity associated with Trazodone hydrochloride. This compound serves as a valuable reference standard for the analysis and characterization of drug formulations. Its characterization is crucial for ensuring the quality and safety of pharmaceutical products containing Trazodone. Research applications include stability testing and compliance with regulatory standards in drug development. -
Drug Impurity
Montelukast impurity 16 is a byproduct associated with the synthesis of Montelukast, a leukotriene receptor antagonist. This reagent is primarily used in pharmacological research to assess the purity and quality of Montelukast formulations. Its utility in stability studies and method validation makes it essential for ensuring compliance with regulatory standards in pharmaceutical development. -
Drug Impurity
Famotidine impurity 5, also known as Famotidine dimer, is a drug impurity associated with famotidine synthesis. This compound serves as a valuable standard for analytical characterization and quality control in pharmaceutical research. Its presence can impact the efficacy and safety of famotidine formulations, making it important for studies on impurity profiling and regulatory compliance. Researchers may utilize this impurity to ensure the integrity of famotidine products and investigate its potential biological relevance. -
Drug Impurity
Olmesartan impurity 11 is a known impurity related to the antihypertensive agent Olmesartan. It is used primarily in the quality control and analytical assessment of Olmesartan formulations. This compound serves as an important reference standard for researchers focusing on drug purity and compliance with pharmacopoeial specifications. Its availability facilitates the evaluation of the stability and safety of Olmesartan in pharmaceutical development. -
Drug Impurity
Olmesartan impurity 6 is a byproduct associated with the synthesis of Olmesartan, an angiotensin II receptor blocker. This compound is primarily utilized to assess the purity and quality of Olmesartan formulations in pharmaceutical research. Its detection and quantification contribute to ensuring compliance with regulatory standards and understanding potential side effects in drug development. -
Drug Impurity
Testosterone impurity 20 is a chemical impurity associated with Testosterone. It serves as a reference standard for quality control and analytical testing in pharmaceutical and biochemistry research. The compound is utilized to evaluate the purity and stability of Testosterone formulations, ensuring compliance with regulatory standards in drug development. -
Drug Impurity
Tramadol impurity 2 is a chemical impurity associated with the analgesic drug Tramadol. This compound is often analyzed during the quality control processes of drug development to assess the purity and safety of pharmaceutical formulations. It serves as a valuable reference standard for toxicological studies and analytical research within regulatory environments. -
Drug Impurity
Tacrolimus impurity 4 is a chemical impurity derived from the immunosuppressive drug Tacrolimus, primarily targeting FKBP12, a key protein involved in T-cell activation. This impurity serves as an important reference standard in quality control and analytical studies focused on the purification and characterization of Tacrolimus formulations. Its analysis aids in ensuring the safety and efficacy of Tacrolimus preparations in pharmaceutical research and development. -
Drug Impurity
Ranitidine impurity 4 hydrochloride is a known impurity associated with Ranitidine hydrochloride. This compound serves as a reference standard for analytical and quality control purposes in pharmaceutical research and development. Its characterization is essential for ensuring the purity and safety of Ranitidine formulations, thereby contributing to regulatory compliance and product integrity in the drug manufacturing process. Researchers utilize this impurity to assess the levels of contaminants and validate analytical methods in their studies. -
Drug Impurity
Atorvastatin Impurity 4 (Calcium) is a structural impurity associated with the statin drug Atorvastatin. It is primarily utilized as a reference standard in quality control and analytical studies to ensure the purity of pharmaceutical formulations. This compound aids in the identification and quantification of impurities, facilitating compliance with regulatory standards in drug development and manufacturing. -
Drug Impurity
Solifenacin impurity 1, also known as Solifenacin impurity C, is identified as a pharmaceutical impurity of the antimuscarinic agent Solifenacin. This compound is primarily used in the quality control and analytical assessment of pharmaceutical formulations. Research applications include stability testing and the evaluation of impurity profiles in drug manufacturing processes. -
Methylprednisolon Impurity
(6a,11β)-11,20-Dihydroxy-6-methyl-3-oxopregna-1,4,17(20)-trien-21-al is an impurity associated with Methylprednisolon. This compound serves as a reference standard in analytical chemistry, particularly for purity assessment and characterization of synthetic processes. Its biological activity may contribute to understanding the profile and metabolism of Methylprednisolon in research applications focused on glucocorticoid studies and steroid hormone analysis. -
Drug Impurity
Rivastigmine impurity 1, also known as N-Desmethyl rivastigmine, is a chemical impurity associated with the cardiovascular activity of Rivastigmine. It is significant in the analysis of drug purity, stability testing, and pharmacokinetic studies. This impurity serves as a valuable reference standard for quality control and method validation in pharmaceutical research. -
Drug Impurity
Pimecrolimus impurity 4, also known as Desmethyl pimecrolimus, is a byproduct of the synthesis of Pimecrolimus. This compound serves as a valuable tool for assessing the purity of Pimecrolimus formulations in research. Its biological relevance and potential impact on drug efficacy make it significant for quality control and pharmaceutical analysis in drug development. -
Lincomycin Impurity
N-Demethyl lincomycin hydrochloride is an impurity derivative of lincomycin, primarily targeting bacterial protein synthesis. This compound exhibits potential activity against various Gram-positive bacteria, making it relevant for investigations into antibiotic resistance and pharmacokinetic studies. It serves as a crucial reference standard for quality control and analysis in lincomycin research. -
Drug Impurity
Rivaroxaban impurity 37 is a known impurity of the anticoagulant drug Rivaroxaban. This compound serves as a reference material for assessing the purity and stability of Rivaroxaban formulations in pharmaceutical development. Its characterization is essential for understanding potential impacts on drug efficacy and safety, making it valuable for quality control and analytical applications in drug research. -
Drug Impurity
Paliperidone impurity 9 is a drug impurity associated with paliperidone, an atypical antipsychotic agent. This compound serves as an important reference standard for the analysis and quantification of paliperidone in pharmaceutical formulations. Its characterization aids in ensuring the quality and safety of therapeutic products and aligns with regulatory standards for drug development and manufacturing. -
Drug Impurity
Terbinafine impurity 14 is a chemical impurity associated with the antifungal agent Terbinafine, primarily acting as a marker for quality control and compliance in pharmaceutical formulations. Its identification and analysis are crucial for ensuring the purity and safety of Terbinafine-containing products. This reagent is primarily utilized in the development and validation of analytical methods in drug manufacturing and quality assurance processes. -
Drug Impurity
Levofloxacin impurity 6 is a characterized impurity associated with Levofloxacin, a fluoroquinolone antibiotic. Its presence in pharmaceutical formulations may impact drug efficacy and safety profiles. This compound is utilized in analytical research for quality control and regulatory compliance, ensuring the purity of Levofloxacin in drug development and manufacturing processes. -
Drug Impurity
Candesartan impurity 20 is a known impurity of the antihypertensive drug Candesartan, primarily targeting the angiotensin II receptor. This compound is utilized in pharmaceutical research to evaluate the purity and quality of Candesartan formulations. It plays a critical role in ensuring compliance with regulatory standards in drug development and quality control processes. -
Drug Impurity
Bupropion impurity 6 hydrochloride is a chemical byproduct associated with the synthesis of Bupropion hydrochloride. This impurity can be utilized in analytical research to assess the quality and purity of Bupropion formulations. Its presence may impact the efficacy and safety profiles of pharmaceutical preparations containing Bupropion, making it relevant for quality control and stability testing in drug development. -
Drug Impurity
Sitagliptin impurity 2 is a known impurity of the antidiabetic agent Sitagliptin, which primarily targets the DPP-4 enzyme. This compound is used in research to investigate the effects of impurities on drug efficacy and safety in therapeutic applications. Its assessment is critical for ensuring the quality and stability of pharmaceutical formulations containing Sitagliptin. -
Drug Impurity
Losartan impurity 7, also known as Losartan trityl ether, is a recognized impurity associated with the synthesis of Losartan. It is primarily utilized in quality control and analytical testing to ensure the purity of pharmaceutical formulations. The identification and quantification of this impurity are critical for adhering to regulatory standards and ensuring the safety and efficacy of Losartan-based medications. -
Drug Impurity
Rivaroxaban impurity 51 is a known impurity associated with the anticoagulant Rivaroxaban. This compound is utilized primarily for quality control and analytical research, validating the purity of Rivaroxaban in pharmaceutical formulations. Its characterization is essential for ensuring compliance with regulatory standards and for understanding the profile of drug impurities in clinical settings. -
Drug Impurity
Prasugrel impurity 3 is a known impurity related to the pharmacological agent Prasugrel. It is primarily utilized in quality control and analytical studies for the assessment of drug purity and consistency. Research applications include the identification and characterization of impurities in pharmaceutical formulations, ensuring compliance with regulatory standards in drug development. -
Drug Impurity
Tenofovir impurity 11, also known as isopropyl tenofovir, serves as an important drug impurity related to Tenofovir synthesis. This compound is utilized primarily in analytical chemistry and quality control studies to evaluate the purity of Tenofovir formulations. Research involving this impurity enhances understanding of synthetic pathways and potential degradation products, supporting improved drug development practices. -
Drug Impurity
Donepezil impurity 6 is a known impurity associated with the cholinesterase inhibitor Donepezil. Its presence is significant for quality control and regulatory compliance in pharmaceutical formulations. This compound can be utilized in research to study the by-products and degradants of Donepezil, aiding in the development of more refined synthetic pathways and enhancing the understanding of drug stability and efficacy. -
Drug Impurity
Fluticasone impurity 2 is a chemical impurity associated with the corticosteroid Fluticasone, primarily identified during pharmaceutical synthesis and analytical studies. This impurity can impact the efficacy and safety profile of Fluticasone formulations, making it critical for quality control and regulatory compliance in drug development. It serves as a reference standard in analytical methods, including HPLC and mass spectrometry, for the characterization of Fluticasone-related compounds.
